Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing

Kyle LaHucik

Senior Reporter

Eli Lilly has tapped another gene editing partner, this time looking to go after a large patient population in the cardiovascular space with the help …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Verve snags $60M from Lil­ly to tack­le Lp(a) with one-time gene edit­ing

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing